Evidence map›Paper›PMID 38222647›Full record

ArticleACS omega2024

Absence of Anaphylactic Reactions to Injection of Hemoglobin Vesicles (Artificial Red Cells) to Rodents.

Hiromi Sakai, Tomoko Kure, Naoko Kobayashi, Tadashi Ito, Yasushi Yamada, Tetsuya Yamada, Rina Miyamoto, Takahito Imaizumi, Jiro Ando, Takaomi Soga and 5 more

Open access · goldAbstract read
In one paragraph

Article in ACS omega, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 3 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 1 country.

Hiromi SakaiDepartment of Chemistry, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.ORCID https://orcid.org/0000-0002-0681-3032
Tomoko KureDepartment of Chemistry, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Naoko KobayashiDepartment of Chemistry, Nara Medical University, 840 Shijo-cho, Kashihara, Nara 634-8521, Japan.
Tadashi ItoNihon Bioresearch Inc., Hashima 501-6251, Japan.
Yasushi YamadaNihon Bioresearch Inc., Hashima 501-6251, Japan.
Tetsuya YamadaNihon Bioresearch Inc., Hashima 501-6251, Japan.
Rina MiyamotoNihon Bioresearch Inc., Hashima 501-6251, Japan.
Takahito ImaizumiNihon Bioresearch Inc., Hashima 501-6251, Japan.
Jiro AndoNihon Bioresearch Inc., Hashima 501-6251, Japan.
Takaomi SogaNihon Bioresearch Inc., Hashima 501-6251, Japan.
Yasuo OsanaiNihon Bioresearch Inc., Hashima 501-6251, Japan.
Makoto OgawaNihon Bioresearch Inc., Hashima 501-6251, Japan.
Taro ShimizuResearch Institute for Microbial Diseases, Osaka University, Suita 565-0871, Japan.
Tatsuhiro IshidaDepartment of Pharmacokinetics and Biopharmaceutics, Institute of Biomedical Sciences, Tokushima University, Tokushima 770-8505, Japan.ORCID https://orcid.org/0000-0002-1333-6465
Hiroshi AzumaDepartment of Pediatrics, Asahikawa Medical University, Asahikawa 078-8510, Japan.
Nara Medical University · JPTokushima University · JPAsahikawa Medical University · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The safety and efficacy of hemoglobin vesicles (HbVs) as artificial oxygen carriers encapsulating a purified and concentrated Hb solution in liposomes have been studied extensively. The HbV surface, modified with PEG by incorporating a PEG-conjugated phospholipid, is beneficial for storage and biocompatibility. However, it might be possible that interaction of PEG and the pre-existing anti-PEG antibody in the bloodstream causes acute adverse reaction. This study used two sets of experiments with rats and guinea pigs to ascertain whether the anti-PEG antibody generated by the PEG-modified HbV injection can induce anaphylactic reactions. SD rats received repeated intravenous injection of HbV at a dose rate of 16 or 32 mL/kg three times. Not anti-PEG IgG but anti-PEG IgM was detected. Nevertheless, no anaphylactic reaction occurred. Guinea pigs were used to study the presence of active systemic anaphylaxis further after injections of the PEG-modified liposomes used for HbV. The animals were sensitized by three repeated subcutaneous injections of PEG-modified liposomes (PEG-liposome) along with adjuvant at 1 week intervals. For comparison, unmodified liposomes (liposome) and 10 times excessively PEG-modified liposomes with ionizable lipid (10PEG-DODAP-liposome) were used. Inclusion of PEG modification induced not only anti-PEG IgM but also anti-PEG IgG. Three weeks after the final injection, intravenous injection of both PEG-liposome and liposome (1 mL/kg) induced no anaphylactic reaction. However, the injection of 10PEG-DODAP-liposome showed one lethal anaphylaxis case and one mild anaphylaxis case. Antisera obtained from the animal sensitized as described above were inoculated (0.05 mL) intradermally into fresh guinea pigs. The presence of passive cutaneous anaphylaxis was evaluated after intravenous injections (1 mL/kg) of three liposomes with Evans blue. No dye leakage was detected at any inoculated skin point for PEG-liposome or liposome, but a slight leakage was detected in one inoculated skin point for 10PEG-DODAP-liposome. These results indicate the absence of acute allergic reactions at repeated injections of HbVs despite the anti-PEG antibody induction. Not all the PEG-modified liposomes show anaphylaxis, and it may depend on the amount of PEGylated phospholipid and lipid composition of PEG-modified liposomes.

Identifiers

PMID38222647
PMCPMC10785325
OpenAlexW4389979778

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.